TM4SF1

Summary

TM4SF1 (transmembrane 4 L six family member 1, HGNC:11853) is a protein-coding gene on chromosome 3q25.1, encoding Transmembrane 4 L6 family member 1 (P30408).

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is a cell surface antigen and is highly expressed in different carcinomas.

Source: NCBI Gene 4071 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 30 total
• MANE Select transcript: NM_014220

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11853
Approved symbol	TM4SF1
Name	transmembrane 4 L six family member 1
Location	3q25.1
Locus type	gene with protein product
Status	Approved
Aliases	L6
Ensembl gene	ENSG00000169908
Ensembl biotype	protein_coding
OMIM	191155
Entrez	4071

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 nonsense_mediated_decay

ENST00000305366, ENST00000472441, ENST00000493298, ENST00000493348, ENST00000868324

RefSeq mRNA: 2 — MANE Select: NM_014220 NM_001410837, NM_014220

CCDS: CCDS3143, CCDS93404

Canonical transcript exons

ENST00000305366 — 5 exons

Exon	Start	End
ENSE00001135802	149375680	149375769
ENSE00001244255	149375443	149375588
ENSE00001244265	149369022	149369880
ENSE00001931310	149377371	149377649
ENSE00003617447	149371687	149371867

Expression profiles

Bgee: expression breadth ubiquitous, 300 present calls, max score 99.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 104.0298 / max 1968.2362, expressed in 1316 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45023	101.4049	1308
45024	2.6249	856

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parietal pleura	UBERON:0002400	99.85	gold quality
vena cava	UBERON:0004087	99.85	gold quality
pleura	UBERON:0000977	99.68	gold quality
cartilage tissue	UBERON:0002418	99.62	gold quality
visceral pleura	UBERON:0002401	99.40	gold quality
germinal epithelium of ovary	UBERON:0001304	99.37	gold quality
epithelium of mammary gland	UBERON:0003244	99.36	gold quality
mammary duct	UBERON:0001765	99.34	gold quality
cervix squamous epithelium	UBERON:0006922	99.26	gold quality
pericardium	UBERON:0002407	99.25	gold quality
tongue squamous epithelium	UBERON:0006919	99.23	gold quality
islet of Langerhans	UBERON:0000006	99.17	gold quality
peritoneum	UBERON:0002358	99.15	gold quality
omental fat pad	UBERON:0010414	99.15	gold quality
gall bladder	UBERON:0002110	99.14	gold quality
lower lobe of lung	UBERON:0008949	99.14	gold quality
calcaneal tendon	UBERON:0003701	99.09	gold quality
mammary gland	UBERON:0001911	99.04	gold quality
thoracic mammary gland	UBERON:0005200	99.03	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.02	gold quality
oral cavity	UBERON:0000167	99.01	gold quality
adipose tissue of abdominal region	UBERON:0007808	99.00	gold quality
tendon of biceps brachii	UBERON:0008188	98.93	gold quality
hair follicle	UBERON:0002073	98.89	gold quality
right coronary artery	UBERON:0001625	98.86	gold quality
upper lobe of lung	UBERON:0008948	98.86	gold quality
upper lobe of left lung	UBERON:0008952	98.83	gold quality
lower esophagus mucosa	UBERON:0035834	98.82	gold quality
esophagus squamous epithelium	UBERON:0006920	98.80	gold quality
minor salivary gland	UBERON:0001830	98.76	gold quality

Single-cell (SCXA)

Detected in 46 experiment(s), a significant marker in 43.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	11158.19
E-MTAB-10855	yes	10644.79
E-MTAB-10137	yes	10439.47
E-CURD-126	yes	7153.28
E-MTAB-8322	yes	6579.13
E-MTAB-9841	yes	5770.77
E-GEOD-135922	yes	5053.05
E-GEOD-130148	yes	4476.38
E-MTAB-10885	yes	4427.59
E-MTAB-8495	yes	4145.28
E-HCAD-15	yes	4013.41
E-MTAB-6308	yes	3643.70
E-GEOD-134144	yes	3343.30
E-MTAB-6678	yes	2646.77
E-MTAB-9906	yes	2379.49

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HNF1A

Literature-anchored findings (GeneRIF, showing 40)

• TAL6 may play a role in cancer invasion and metastasis (PMID:12855661)
• These data suggest that L6-Ag influences cell motility via TERM by regulating the surface presentation and endocytosis of some of their components. (PMID:18270265)
• The gene ratio test with the TM4SF1 gene for survival of patients with malignant pleural mesothelioma has robust predictive value. (PMID:19401544)
• TM4SF1 can serve as a surface protein marker which singly identifies MSCs from diverse cell sources, in particular, fibroblast-rich connective tissues (PMID:20486778)
• We provide evidence that ARHGDIA, COBLL1, and TM4SF1 are negative regulators of apoptosis in cultured tumor cells. (PMID:21569526)
• TM4SF1, like genuine tetraspanins, serves as a molecular organizer that interacts with membrane and cytoskeleton-associated proteins and uniquely initiates the formation of nanopodia and facilitates cell polarization and migration. (PMID:21626280)
• Inhibition of cell migration after targeted knockdown of TM4SF1 protein expression suggests its contribution to prostate cancer cell metastasis. (PMID:21656834)
• High TM4SF1 expression is associated with pancreatic cancer. (PMID:24285464)
• TM4SF1 is a small plasma membrane glycoprotein that regulates cell motility and proliferation, and possibly a new vascular therapeutic target in cancer (PMID:24986520)
• Transmembrane-4-L-six-family-1 is overexpressed in human gliomas in general and the precise level of expression might predict outcome and could be of clinical value. (PMID:25855954)
• We found that miR-203 was significantly downregulated in OSF tissues compared to that in normal buccal mucosa tissues, and that miR-203 negatively regulated secreted SFRP4 and positively regulated TM4SF1 (PMID:25872484)
• Study shows that TM4SF1 expression is associated with better prognosis in pancreatic cancer. Its loss contributes to the invasion and migration of pancreatic cancer cells. (PMID:26035794)
• These findings validate TM4SF1 as an attractive candidate for cancer therapy with antibody-bound toxins that have the capacity to react with either cytoplasmic or nuclear targets in tumor cells or tumor-associated vascular endothelium. (PMID:26241677)
• TM4SF1 overexpression significantly contributed MDA-MB-231 cell migration but decreased apoptotic cells (PMID:26464650)
• The findings suggest that TM4SF1 is a surface membrane antigen that is highly expressed in pancreatic cancer cells and increases the chemoresistance to gemcitabine. TM4SF1 may be a promising target to overcome the chemoresistance of pancreatic cancer. (PMID:26709920)
• Results show that TM4SF1 expression is elevated in colorectal cancer (CRC), and associated with tumor stage and lymph node metastasis. Also, miR-9 directly targeted its binding site in the TM4SF1 3’-UTR, which has a critical role in regulating CRC cell migration. and invasion. Furthermore, miR-9 regulated cell motility via suppressing (PMID:26983891)
• Results indicate that the expression of transmembrane 4 L6 family member 1 (TM4SF1) is higher in pancreatic cancer tissues and pancreatic cancer cell lines than controls. (PMID:27459514)
• High TM4SF1 expression is associated with esophageal cancer. (PMID:27974706)
• Replacement of the transmembrane 4 L six family protein TM4SF1 or TM4SF4 C-terminus with that of TM4SF5 increased spheroids growth, transwell migration, and invasive dissemination from spheroids in 3D collagen gels. (PMID:28129652)
• our study provides a novel regulatory pathway involving TM4SF1, DDR1, MMP2 and MMP9, which promotes the formation and function of invadopodia to support cell migration and invasion in pancreatic cancer. (PMID:28368050)
• Results suggest that miR-30a is an important regulator of TM4SF1, VEGF, and E-cadherin for CRC lymph node metastasis, a potential new therapeutic target in CRC. (PMID:28528497)
• Regulation of transmembrane-4-L-six-family-1 (TM4SF1) on bladder cancer cell could be induced by peroxisome proliferator-activated receptor gamma (PPARgamma)-sirtuin 1 (SIRT1) feedback loop. (PMID:29175458)
• TM4SF1 was recognized as a direct target for miR-520f in hepatocellular carcinoma (HCC) cells where its expression was found up-regulated and inversely correlated with that of mir-520f. (PMID:29505836)
• These data suggested that low expression of TM4SF1 is associated with carcinogenesis and development, tumor progression and invasion of gastric cancer, and poor overall survival of patients with GC. TM4SF1 is a tumor suppressor for GC and a novel prognostic marker for patients with GC. (PMID:29665316)
• These results could be reversed by the overexpression of TM4SF1. At last, up-regulation of miR-206 suppressed expression of p-AKT and p-ERK by targetting TM4SF1 in PGE2-induced cells.Our results provide further evidence that miR-206 has a protective effect on PGE2-induced colon carcinogenesis. (PMID:30135139)
• our data provide the first evidence that TM4SF1 is a direct target of miR-30a/c and miR-30a/c inhibits the stemness and proliferation of NSCLC cells by targeting TM4SF1, suggesting that miR-30a/c and TM4SF1 may be useful as tumor biomarkers for the diagnosis and treatment of NSCLC patients. (PMID:30301667)
• Results find that TM4SF1 has selective expression features in epithelial ovarian tumors, can mediate tumor cell growth and invasion, as well as metastasis, and is closely associated with anti-tumor immune responses. (PMID:30876464)
• TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates beta-catenin/TCF signalling. (PMID:31876386)
• High TM4SF1 expression is associated with metastasis in prostate cancer. (PMID:31983129)
• TM4SF1 facilitates non-small cell lung cancer progression through regulating YAP-TEAD pathway. (PMID:32141552)
• found miR-1-3p and miR-214-5p targeted TM4SF1, inhibited TM4SF1 expression, cell proliferation, migration, and induced apoptosis in human keloid fibroblasts (PMID:32376266)
• TM4SF1 promotes EMT and cancer stemness via the Wnt/beta-catenin/SOX2 pathway in colorectal cancer. (PMID:33153498)
• HIF-1alpha-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression. (PMID:34118595)
• Hyper-expression and hypomethylation of TM4SF1 are associated with lymph node metastases in papillary thyroid carcinoma patients. (PMID:35081723)
• TM4SF1 promotes glioma malignancy through multiple mechanisms. (PMID:35532297)
• Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion. (PMID:35730016)
• TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin alpha6. (PMID:35835740)
• Tm4sf1-marked Endothelial Subpopulation Is Dysregulated in Pulmonary Arterial Hypertension. (PMID:36252184)
• MicroRNA-501-3p targeting TM4SF1 facilitates tumor-related behaviors of gastric cancer cells via EMT signaling pathway. (PMID:36274500)
• TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC. (PMID:37069693)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tm4sf1	ENSMUSG00000027800
rattus_norvegicus	Tm4sf1	ENSRNOG00000015812

Paralogs (5): TM4SF5 (ENSG00000142484), TM4SF19 (ENSG00000145107), TM4SF18 (ENSG00000163762), TM4SF20 (ENSG00000168955), TM4SF4 (ENSG00000169903)

Protein

Protein identifiers

Transmembrane 4 L6 family member 1 — P30408 (reviewed: P30408)

Alternative names: Membrane component chromosome 3 surface marker 1, Tumor-associated antigen L6

All UniProt accessions (4): P30408, C9J611, F8WBG6, F8WF27

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Present in high molecular weight complexes in tumor cells. Interacts with SDCBP2.

Subcellular location. Membrane.

Tissue specificity. Highly expressed in lung, breast, colon and ovarian carcinomas. It is also present on some normal cells, endothelial cells in particular.

Similarity. Belongs to the L6 tetraspanin family.

RefSeq proteins (2): NP_001397766, NP_055035* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008661	L6_membrane	Family

Pfam: PF05805

UniProt features (13 total): topological domain 5, transmembrane region 4, glycosylation site 2, chain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30408-F1	80.47	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 129, 159

Mutagenesis-validated functional residues (1):

Position	Phenotype
202	abolishes interaction with sdcbp2. loss of colocalization with sdcbp2 at the apical region of the cell.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 293 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MODULE_52, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, JAEGER_METASTASIS_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, KENNY_CTNNB1_TARGETS_UP, GENTILE_RESPONSE_CLUSTER_D3, GOBP_BLASTOCYST_FORMATION, GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN, OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP, MODULE_118, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP

GO Biological Process (1): blastocyst formation (GO:0001825)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
blastocyst development	1
anatomical structure formation involved in morphogenesis	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

950 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TM4SF1	DDR1	Q08345	862
TM4SF1	TSPAN1	O60635	793
TM4SF1	B4E171	B4E171	761
TM4SF1	ITGA5	P08648	715
TM4SF1	CD37	P11049	666
TM4SF1	ITGB1	P05556	656
TM4SF1	CD53	P19397	654
TM4SF1	ITGB5	P18084	652
TM4SF1	TSPAN31	Q12999	632
TM4SF1	CD9	P21926	627
TM4SF1	MYO10	Q9HD67	626
TM4SF1	ANPEP	P15144	624
TM4SF1	CD63	P08962	593
TM4SF1	TSPAN6	O43657	584
TM4SF1	CDHR1	Q96JP9	548

IntAct

11 interactions, top by confidence:

A	B	Type	Score
SDCBP2	TM4SF1	psi-mi:“MI:0915”(physical association)	0.540
TM4SF1	SDCBP2	psi-mi:“MI:0915”(physical association)	0.540
SDCBP2	TM4SF1	psi-mi:“MI:0403”(colocalization)	0.540
TM4SF1	E6	psi-mi:“MI:0915”(physical association)	0.370
	NBAS	psi-mi:“MI:0914”(association)	0.350
malS	TM4SF1	psi-mi:“MI:0915”(physical association)	0.000
TM4SF1	DDR1	psi-mi:“MI:0915”(physical association)	0.000
HSPA8	TM4SF1	psi-mi:“MI:0915”(physical association)	0.000
TM4SF1	TUBA4A	psi-mi:“MI:0915”(physical association)	0.000
TM4SF1	DNAJA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): TM4SF1 (Affinity Capture-RNA), TM4SF1 (Synthetic Lethality), TM4SF1 (PCA), DNAJA1 (Two-hybrid), TM4SF1 (Two-hybrid), Tuba1a (Two-hybrid), DDR1 (Two-hybrid), TM4SF1 (Affinity Capture-MS), TM4SF1 (Two-hybrid), TM4SF1 (Affinity Capture-MS), TM4SF1 (Proximity Label-MS), TM4SF1 (Affinity Capture-RNA)

ESM2 similar proteins: A2VE58, A3KQ86, A6H7B0, A6NC51, A6NDP7, A6NFC5, B1AQL3, B2RZ87, E9Q9H8, O14894, O43761, P0C5X8, P30408, P47987, Q08AU7, Q08DL4, Q13021, Q1HG44, Q2KIG8, Q2KJ98, Q3UUA0, Q49LS7, Q4VV71, Q58CW5, Q5RE43, Q5RFC1, Q5XGR0, Q63175, Q63ZU3, Q64302, Q6DFR5, Q7TQJ1, Q7Z7N9, Q8BHJ6, Q8K177, Q8R191, Q91X49, Q923Z0, Q96DZ7, Q9BSK0

Diamond homologs: E9Q9H8, O14894, P30408, P48230, P49111, Q2KIG8, Q5R6Z4, Q5RE43, Q64302, Q91XD3, Q96DZ7, Q9EQL5, Q3T110, Q53R12, Q96CE8, Q9CQY8, Q3T0Z4

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
DDR1	“up-regulates activity”	TM4SF1	binding
TM4SF1	“up-regulates activity”	SDCBP2	relocalization
TM4SF1	“up-regulates activity”	DVL2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

613 predictions. Top by Δscore:

Variant	Effect	Δscore
3:149371866:ACC:A	acceptor_loss	1.0000
3:149371867:CCTGT:C	acceptor_loss	1.0000
3:149371868:C:A	acceptor_loss	1.0000
3:149371869:T:G	acceptor_loss	1.0000
3:149375437:A:AC	donor_gain	1.0000
3:149375438:C:CC	donor_gain	1.0000
3:149375438:CATA:C	donor_gain	1.0000
3:149375441:A:AC	donor_gain	1.0000
3:149375442:C:CT	donor_gain	1.0000
3:149375442:CTGG:C	donor_gain	1.0000
3:149375678:A:AC	donor_gain	1.0000
3:149375679:C:CC	donor_gain	1.0000
3:149369876:TATTG:T	acceptor_gain	0.9900
3:149369878:TTG:T	acceptor_gain	0.9900
3:149369881:C:CC	acceptor_gain	0.9900
3:149371681:TCTTA:T	donor_loss	0.9900
3:149371682:CTTAC:C	donor_loss	0.9900
3:149371683:TTA:T	donor_loss	0.9900
3:149371684:TA:T	donor_loss	0.9900
3:149371685:A:AG	donor_loss	0.9900
3:149371686:CCT:C	donor_loss	0.9900
3:149371863:GGTAC:G	acceptor_gain	0.9900
3:149371865:TAC:T	acceptor_gain	0.9900
3:149371868:C:CC	acceptor_gain	0.9900
3:149374472:A:AC	donor_gain	0.9900
3:149374473:G:C	donor_gain	0.9900
3:149374481:T:TA	donor_gain	0.9900
3:149375441:ACTGG:A	donor_gain	0.9900
3:149375442:CTGGC:C	donor_gain	0.9900
3:149375445:G:A	donor_gain	0.9900

AlphaMissense

1306 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:149371809:A:G	W158R	0.993
3:149371809:A:T	W158R	0.993
3:149371835:C:G	C149S	0.993
3:149371836:A:T	C149S	0.993
3:149371807:C:A	W158C	0.990
3:149371807:C:G	W158C	0.990
3:149377473:A:C	N25K	0.990
3:149377473:A:T	N25K	0.990
3:149371843:C:A	W146C	0.988
3:149371843:C:G	W146C	0.988
3:149371834:G:C	C149W	0.987
3:149375494:C:G	C121S	0.987
3:149375495:A:T	C121S	0.987
3:149371836:A:G	C149R	0.986
3:149375493:A:C	C121W	0.986
3:149375504:C:G	G118R	0.986
3:149375504:C:T	G118R	0.986
3:149375472:C:A	W128C	0.985
3:149375472:C:G	W128C	0.985
3:149375495:A:G	C121R	0.984
3:149377416:G:C	S44R	0.984
3:149377416:G:T	S44R	0.984
3:149377418:T:G	S44R	0.984
3:149375557:C:T	G100E	0.983
3:149371752:A:G	C177R	0.982
3:149375461:A:C	F132C	0.981
3:149375558:C:G	G100R	0.981
3:149375558:C:T	G100R	0.981
3:149375503:C:T	G118E	0.980
3:149375548:C:T	G103E	0.979

dbSNP variants (sampled 300 via entrez): RS1000322759 (3:149379041 C>A,T), RS1000382146 (3:149372587 G>A), RS1000544177 (3:149375779 A>G), RS1000816347 (3:149372945 C>G), RS1001131541 (3:149369539 T>C), RS1001427536 (3:149379062 G>A), RS1001500663 (3:149369246 T>C), RS1001607139 (3:149379216 G>A), RS1002226961 (3:149378757 A>AT), RS1002626453 (3:149373724 T>G), RS1002845732 (3:149370475 G>A), RS1002880042 (3:149370913 C>A,T), RS1004243792 (3:149375197 C>A,G), RS1004378569 (3:149373656 A>C), RS1004598902 (3:149369967 C>T)

Disease associations

OMIM: gene MIM:191155 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90011898_152	Alanine aminotransferase levels	7.000000e-23

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

90 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	6
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	5
Tetrachlorodibenzodioxin	increases expression, affects expression, decreases expression	5
Cadmium	decreases expression, increases expression, decreases reaction	4
Estradiol	decreases expression, decreases reaction, affects cotreatment	4
Valproic Acid	affects expression, decreases expression, increases expression	4
bisphenol A	increases expression, affects expression, decreases expression	3
Calcitriol	decreases expression, increases expression, affects cotreatment	3
Cyclosporine	decreases expression	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
(+)-JQ1 compound	decreases expression	2
Arsenic Trioxide	decreases expression, increases expression	2
Fulvestrant	increases expression, increases methylation, decreases expression, decreases reaction	2
Acetaminophen	decreases expression	2
Arsenic	affects cotreatment, decreases expression, increases abundance	2
Folic Acid	affects expression, decreases expression	2
Isoflavones	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Quercetin	affects cotreatment, increases expression	2
Silicon Dioxide	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Aflatoxin B1	affects expression, increases expression	2
Asbestos, Crocidolite	decreases expression, increases expression	2
Cadmium Chloride	increases expression, affects cotreatment, decreases expression	2
tert-Butylhydroperoxide	increases expression	2
aristolochic acid I	increases expression	1
N-(1,3-dimethylbutyl)-N’-phenyl-p-phenylenediamine quinone	affects expression	1
urushiol	increases expression	1
methylmercuric chloride	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2IP	Abcam HeLa TM4SF1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.